# Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

> **NCT04034251** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastric Cancer
- Esophagogastric Junction
- Peritoneal Carcinomatosis

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Capecitabine
- **DEVICE:** BardPort Titanium Implanted Port with Peritoneal Catheter

## Key facts

- **NCT ID:** NCT04034251
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-09
- **Primary completion:** 2023-02-25
- **Final completion:** 2024-09-05
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment in another study.
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034251, "Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04034251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*